Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 3.64 EUR 4%
Market Cap: 695.3m EUR

Inventiva SA
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Inventiva SA
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Inventiva SA
PAR:IVA
EPS (Diluted)
-€2
CAGR 3-Years
-28%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
EPS (Diluted)
€0
CAGR 3-Years
29%
CAGR 5-Years
-14%
CAGR 10-Years
-12%
Nanobiotix SA
PAR:NANO
EPS (Diluted)
-€1
CAGR 3-Years
4%
CAGR 5-Years
12%
CAGR 10-Years
0%
Cellectis SA
PAR:ALCLS
EPS (Diluted)
$0
CAGR 3-Years
42%
CAGR 5-Years
16%
CAGR 10-Years
1%
DBV Technologies SA
PAR:DBV
EPS (Diluted)
-$1
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
3%
Eurobio Scientific SA
PAR:ALERS
EPS (Diluted)
€0
CAGR 3-Years
-63%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
No Stocks Found

Inventiva SA
Glance View

Market Cap
695.3m EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
1.99 EUR
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Inventiva SA's EPS (Diluted)?
EPS (Diluted)
-2.9 EUR

Based on the financial report for Jun 30, 2025, Inventiva SA's EPS (Diluted) amounts to -2.9 EUR.

What is Inventiva SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-28%

Over the last year, the EPS (Diluted) growth was -43%. The average annual EPS (Diluted) growth rates for Inventiva SA have been -28% over the past three years , -28% over the past five years .

Back to Top